vs
Churchill Downs Inc（CHDN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Churchill Downs Inc的1.2倍（$772.1M vs $663.0M），Revvity净利率更高（12.7% vs 12.5%，领先0.2%），Revvity同比增速更快（5.9% vs 3.1%），过去两年Revvity的营收复合增速更高（9.0% vs -13.7%）
丘吉尔唐斯股份有限公司是丘吉尔唐斯赛马场的母公司，起家于美国肯塔基州路易斯维尔的单一赛马场，现已发展为业务覆盖美国多州的上市企业，旗下拥有赛马场、赌场、线上投注平台等多元业务板块。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CHDN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$663.0M
营收增速更快
RVTY
高出2.7%
3.1%
净利率更高
RVTY
高出0.2%
12.5%
两年增速更快
RVTY
近两年复合增速
-13.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $663.0M | $772.1M |
| 净利润 | $83.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 21.6% | 14.5% |
| 净利率 | 12.5% | 12.7% |
| 营收同比 | 3.1% | 5.9% |
| 净利润同比 | 7.8% | 3.9% |
| 每股收益（稀释后） | $1.16 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHDNRVTY
| Q1 26 | $663.0M | — | ||
| Q4 25 | $665.9M | $772.1M | ||
| Q3 25 | $683.0M | $698.9M | ||
| Q2 25 | $934.4M | $720.3M | ||
| Q1 25 | $642.6M | $664.8M | ||
| Q4 24 | $624.2M | $729.4M | ||
| Q3 24 | $628.5M | $684.0M | ||
| Q2 24 | $890.7M | $691.7M |
净利润CHDNRVTY
| Q1 26 | $83.0M | — | ||
| Q4 25 | $51.3M | $98.4M | ||
| Q3 25 | $38.1M | $46.7M | ||
| Q2 25 | $216.9M | $53.9M | ||
| Q1 25 | $76.7M | $42.2M | ||
| Q4 24 | $71.7M | $94.6M | ||
| Q3 24 | $65.4M | $94.4M | ||
| Q2 24 | $209.3M | $55.4M |
毛利率CHDNRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率CHDNRVTY
| Q1 26 | 21.6% | — | ||
| Q4 25 | 18.5% | 14.5% | ||
| Q3 25 | 14.3% | 11.7% | ||
| Q2 25 | 35.1% | 12.6% | ||
| Q1 25 | 20.9% | 10.9% | ||
| Q4 24 | 20.3% | 16.3% | ||
| Q3 24 | 20.0% | 14.3% | ||
| Q2 24 | 37.0% | 12.4% |
净利率CHDNRVTY
| Q1 26 | 12.5% | — | ||
| Q4 25 | 7.7% | 12.7% | ||
| Q3 25 | 5.6% | 6.7% | ||
| Q2 25 | 23.2% | 7.5% | ||
| Q1 25 | 11.9% | 6.4% | ||
| Q4 24 | 11.5% | 13.0% | ||
| Q3 24 | 10.4% | 13.8% | ||
| Q2 24 | 23.5% | 8.0% |
每股收益（稀释后）CHDNRVTY
| Q1 26 | $1.16 | — | ||
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $200.0M | $919.9M |
| 总债务越低越好 | $840.0M | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $7.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CHDNRVTY
| Q1 26 | $200.0M | — | ||
| Q4 25 | $200.6M | $919.9M | ||
| Q3 25 | $180.5M | $931.4M | ||
| Q2 25 | $182.4M | $991.8M | ||
| Q1 25 | $174.2M | $1.1B | ||
| Q4 24 | $175.5M | $1.2B | ||
| Q3 24 | $152.7M | $1.2B | ||
| Q2 24 | $140.3M | $2.0B |
总债务CHDNRVTY
| Q1 26 | $840.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CHDNRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $7.3B | ||
| Q3 25 | $1.0B | $7.4B | ||
| Q2 25 | $1.0B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.0B | $7.9B |
总资产CHDNRVTY
| Q1 26 | $7.5B | — | ||
| Q4 25 | $7.5B | $12.2B | ||
| Q3 25 | $7.5B | $12.1B | ||
| Q2 25 | $7.4B | $12.4B | ||
| Q1 25 | $7.3B | $12.4B | ||
| Q4 24 | $7.3B | $12.4B | ||
| Q3 24 | $7.2B | $12.8B | ||
| Q2 24 | $7.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $295.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 3.55× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流CHDNRVTY
| Q1 26 | $295.0M | — | ||
| Q4 25 | — | $182.0M | ||
| Q3 25 | $187.7M | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | $246.5M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $169.4M | $147.9M | ||
| Q2 24 | — | $158.6M |
自由现金流CHDNRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | $166.3M | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | $233.9M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $154.4M | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率CHDNRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | 24.3% | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | 36.4% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 24.6% | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度CHDNRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 2.6% | ||
| Q3 25 | 3.1% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 5.4% | 3.4% | ||
| Q3 24 | 2.4% | 3.3% | ||
| Q2 24 | 2.5% | 3.2% |
现金转化率CHDNRVTY
| Q1 26 | 3.55× | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 4.93× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 3.21× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.59× | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHDN
| Live and Historical Racing | $297.0M | 45% |
| Gaming | $257.0M | 39% |
| Wagering Services and Solutions | $109.0M | 16% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
